3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
18
Melanoma
16
Triple Negative Breast Neoplasms
13
Colorectal Neoplasms
11
Neoplasms
9
Neoplasm Metastasis
9
Squamous Cell Carcinoma of Head and Neck
7
Pancreatic Neoplasms
7
Carcinoma, Renal Cell
7
Stomach Neoplasms
6
Lymphoma
6
Uterine Cervical Neoplasms
5
Ovarian Neoplasms
5
Lung Neoplasms
4
Liver Neoplasms
4
Head and Neck Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Esophageal Neoplasms
4
Endometrial Neoplasms
4
Breast Neoplasms
4
Small Cell Lung Carcinoma
3
Sarcoma
3
Nasopharyngeal Carcinoma
3
Colonic Neoplasms
3
Carcinoma, Hepatocellular
3
Advanced Solid Tumor
3
Solid Tumors
2
Solid Tumor, Adult
2
Recurrence
2
Rectal Neoplasms
2
Interventions
pembrolizumab
20
Cisplatin
17
Cetuximab
13
Docetaxel
11
Paclitaxel
9
Carboplatin
9
Radiotherapy
8
Fluorouracil
6
cemiplimab
5
130-nm albumin-bound paclitaxel
5
Bleomycin
4
Radiation
3
Pemetrexed
3
Panitumumab
3
Nivolumab
3
Gemcitabine
3
Albumin-Bound Paclitaxel
3
vandetanib
2
talimogene laherparepvec
2
selinexor
2
motexafin gadolinium
2
figitumumab
2
brigatinib
2
avelumab
2
atezolizumab
2
alpha-2'-deoxythioguanosine
2
advexin
2
Taxes
2
ON 01910
2
Methotrexate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Squamous Cell
×
spartalizumab
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts